Table II.

Change in Lipid Parameters After 3 Months of Aromatase Inhibitor Therapy in the Overall Lipid Analysis Cohort (n = 246)

	Entire Cohort (n = 246)				Exemestane Group (n = 117)				Letrozole Group (n = 129)
	Baseline	3 Months	Change, Mean ± SD (%)	P Value	Baseline	3 Months	Change, Mean ± SD (%)	P Value	Baseline	3 Months	Change, Mean ± SD (%)	P Value
Total cholesterol, mg/dL	208 ± 35	208 ± 33	0.3 ± 27 (<1)	.847	212 ± 36	205 ± 34	−8 ± 28 (4)	.003	203 ± 35	211 ± 33	8 ± 24 (4)	<.001
HDL, mg/dL	62 ± 17	57 ± 17	−4 ± 9 (7)	<.001	63 ± 18	55 ±16	−8 ± 9 (12)	<.001	60 ± 17	59 ± 17	−1 ± 9 (2)	.169
LDL, mg/dL	124 ± 32	129 ± 29	5 ± 26 (4)	.005	127 ± 32	129 ± 28	2 ± 27 (2)	.361	121 ± 31	128 ± 30	7 ± 25 (5)	.002
LDL/HDL Ratio	2.2 ± 0.9	2.4 ± 0.9	0.2 ± 0.6 (8)	<.001	2.2 ± 0.9	2.5 ± 0.9	0.3 ± 0.6 (12)	<.001	2.2 ± 0.9	2.4 ± 0.9	0.2 ± 0.5 (8)	<.001
TG, mg/dL	111 ± 53	106 ± 48	−5 ± 43 (5)	.053	112 ± 53	101 ± 45	−12 ± 42 (10)	.003	110 ± 54	110 ± 50	0.4 ± 43 (<1)	.922

Values are shown as mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.